FDA accepts Shorla’s oral liquid leukaemia drug NDA
The FDA has approved the NDA for SH-201, an oral liquid drug that slows or stops the growth of certain types of leukaemia.
The FDA has approved the NDA for SH-201, an oral liquid drug that slows or stops the growth of certain types of leukaemia.
What's Your Reaction?
